Bile acid receptors as targets for drug development

Bile salt biotransformations by human intestinal bacteria

Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829

Identification of a nuclear receptor for bile acids

Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714

Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist

Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220

The Enzymes, Regulation, and Genetics of Bile Acid Synthesis

Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069

A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis

Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865

EASL Clinical Practice Guidelines: management of cholestatic liver diseases

European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729

A G Protein-coupled Receptor Responsive to Bile Acids

Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628

Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions

Prakash, C., Zuniga, B., Song, C. S., Jiang, S., Cropper, J. D., Park, S.-G., & Chatterjee, B. (2015) · Nuclear Receptor Research · doi:10.11131/2015/101178 · Cited by 105

Chemoproteomic Profiling of Bile Acid Interacting Proteins

Zhuang, S., Li, Q., Cai, L., Wang, C., & Lei, X. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00134 · Cited by 106

FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice

Iracheta‐Vellve, A., Calenda, C. D., Petrášek, J., Ambade, A., Kodys, K., Adorini, L., & Szabó, G. (2018) · Hepatology Communications · doi:10.1002/hep4.1256 · Cited by 107

Identification of functional farnesoid X receptors in brain neurons

Huang, C., Wang, J., Hu, W., Wang, C., Lu, X., Tong, L., Wu, F., & Zhang, W. (2016) · FEBS Letters · doi:10.1002/1873-3468.12373 · Cited by 103

Activation of TGR5 with INT-777 attenuates oxidative stress and neuronal apoptosis via cAMP/PKCε/ALDH2 pathway after subarachnoid hemorrhage in rats

Zuo, G., Zhang, T., Huang, L., Araujo, C., Peng, J., Travis, Z. D., Okada, T., Ocak, U., Zhang, G., Tang, J., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.09.002 · Cited by 103

Interactions between bile salts, gut microbiota, and hepatic innate immunity

Schubert, K. A., Damink, S. W. M. O., von Bergen�, M., & Schaap, F. G. (2017) · Immunological Reviews · doi:10.1111/imr.12579 · Cited by 104

Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice

Zhang, X., Huang, S., Gao, M., Liu, J., Jia, X., Han, Q., Zheng, S., Miao, Y., Li, S., Weng, H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323977111 · Cited by 102

The Gut-Liver Axis in Cholestatic Liver Diseases

Blesl, A., & Stadlbauer, V. (2021) · Nutrients · doi:10.3390/nu13031018 · Cited by 102

Critical roles of bile acids in regulating intestinal mucosal immune responses

Sun, R., Xu, C., Feng, B., Gao, X., & Liu, Z. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211018098 · Cited by 105

Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts

Trivedi, P. J., Hirschfield, G. M., Adams, D., & Vierling, J. M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.049 · Cited by 101

Bile acids affect intestinal barrier function through FXR and TGR5

Song, G., Xie, Y., Yi, L., Cheng, W., Jia, H., Shi, W., Liu, Q., Fang, L., Xue, S., Liu, D., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1607899 · Cited by 111

Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study

Varma, V. R., Wang, Y., An, Y., Varma, S., Bilgel, M., Doshi, J., Legido-Quigley, C., Delgado, J. C., Oommen, A. M., Roberts, J. A., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003615 · Cited by 97

Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease

Wunsch, E., Milkiewicz, M., Wasik, U., Trottier, J., Kempińska‐Podhorodecka, A., Elias, E., Barbier, O., & Milkiewicz, P. (2015) · Scientific Reports · doi:10.1038/srep13462 · Cited by 97

G-Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5) Agonists Reduce the Production of Proinflammatory Cytokines and Stabilize the Alternative Macrophage Phenotype

Hoegenauer, K., Arista, L., Schmiedeberg, N., Werner, G., Jaksche, H., Bouhelal, R., Nguyen, D. G., Bhat, B. G., Raad, L., Rauld, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501052c · Cited by 98

Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents

Hernandez, E. D., Zheng, L., Kim, Y., Fang, B., Liu, B., Valdez, R., Dietrich, W. F., Rucker, P. V., CHIANELLI, D., Schmeits, J., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1368 · Cited by 94

The regulation of PKA signaling in obesity and in the maintenance of metabolic health

London, E., & Stratakis, C. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108113 · Cited by 99

FXR and liver carcinogenesis

Huang, X., Zhao, W., & Huang, W. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.117 · Cited by 98

Molecular features of bile salt hydrolases and relevance in human health

Chand, D., Avinash, V. S., Yadav, Y., Pundle, A. V., Suresh, C. G., & Ramasamy, S. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.09.024 · Cited by 98

The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity

He, Y., Shaoyong, W., Chen, Y., Li, M., Gan, Y., Sun, L., Liu, Y., Wang, Y., & Jin, M. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.05.015 · Cited by 107

Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling

Keune, W., Hausmann, J., Bolier, R., Tolenaars, D., Kremer, A. E., Heidebrecht, T., Joosten, R. P., Sunkara, M., Morris, A. J., Matas-Rico, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms11248 · Cited by 92

Ileal FGF 15 contributes to fibrosis‐associated hepatocellular carcinoma development

Uriarte, I., Latasa, M. U., Carotti, S., Fernández‐Barrena, M. G., García‐Irigoyen, O., Elizalde, M., Urtasun, R., Gentilucci, U. V., Morini, S., Pulido, Á. D. M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29287 · Cited by 88

Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1)

Sepe, V., Renga, B., Festa, C., D’Amore, C., Masullo, D., Cipriani, S., Leva, F. S. D., Monti, M. C., Novellino, E., Limongelli, V., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500889f · Cited by 89

Regeneration Defects in Yap and Taz Mutant Mouse Livers Are Caused by Bile Duct Disruption and Cholestasis

Verboven, E., Moya, I. M., Sansores-Garcia, L., Xie, J., Hillen, H., Kowalczyk, W., Vella, G., Verhulst, S., Castaldo, S. A., Algueró-Nadal, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.035 · Cited by 87

The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective

Wang, L., Cao, Z.-M., Zhang, L., Li, J.-M., & Lv, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923599 · Cited by 89

Human Postprandial Nutrient Metabolism and Low-Grade Inflammation: A Narrative Review

Meessen, E. C. E., Warmbrunn, M. V., Nieuwdorp, M., & Soeters, M. R. (2019) · Nutrients · doi:10.3390/nu11123000 · Cited by 95

Protective effects of taurocholic acid on excessive hepatic lipid accumulation via regulation of bile acid metabolism in grouper

Xu, J., Xie, S., Chi, S., Zhang, S., Cao, J., & Tan, B. (2022) · Food & Function · doi:10.1039/d1fo04085e · Cited by 84

Bile Acid Homeostasis in a Cholesterol 7α‐Hydroxylase and Sterol 27‐Hydroxylase Double Knockout Mouse Model

Rizzolo, D., Buckley, K., Kong, B., Zhan, L., Shen, J., Stofan, M., Brinker, A., Goedken, M., Buckley, B., & Guo, G. L. (2019) · Hepatology · doi:10.1002/hep.30612 · Cited by 83

Nonsteroidal FXR Ligands: Current Status and Clinical Applications

Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83

Pharmacological Treatment for Non-alcoholic Fatty Liver Disease

Francque, S., & Vonghia, L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00898-6 · Cited by 83

Fxr signaling and microbial metabolism of bile salts in the zebrafish intestine

Wen, J., Mercado, G. P., Volland, A., Doden, H. L., Lickwar, C. R., Crooks, T. A., Kakiyama, G., Kelly, C., Cocchiaro, J. L., Ridlon, J. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg1371 · Cited by 85

Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity

Jin, W., Xiao, L., Jeong, M., Han, S.-J., Zhang, W., Yano, H., Shi, H., Arifuzzaman, M., Lyu, M., Wang, D., et al. (2025) · Cell · doi:10.1016/j.cell.2025.02.029 · Cited by 94

Activation of bile acid signaling improves metabolic phenotypes in high-fat diet-induced obese mice

Pierre, J. F., Martinez, K., Ye, H., Nadimpalli, A., Morton, T. C., Yang, J., Wang, Q., Patno, N., Chang, E. B., & Yin, D. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00202.2016 · Cited by 83

Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice

Finn, P. D., Rodriguez, D. J., Kohler, J. N., Jiang, Z., Wan, S., Blanco, E. J., King, A. J., Chen, T., Bell, N., Dragoli, D. R., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00300.2018 · Cited by 82

Pathogenesis and Management of Pruritus in PBC and PSC

Kremer, A. E., Namer, B., Bolier, R., Fischer, M. J. M., Elferink, R. P. J. O., & Beuers, U. H. (2015) · Digestive Diseases · doi:10.1159/000440829 · Cited by 84

Takeda G Protein–Coupled Receptor 5 Modulates Depression-like Behaviors via Hippocampal CA3 Pyramidal Neurons Afferent to Dorsolateral Septum

Wang, H., Tan, Y.-Z., Mu, R.-H., Tang, S., Liu, X., Xing, S.-Y., Long, Y., Yuan, D.-H., & Hong, H. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.11.018 · Cited by 81

Baitouweng Tang ameliorates DSS-induced ulcerative colitis through the regulation of the gut microbiota and bile acids via pathways involving FXR and TGR5

Hua, Y., Jia, Y., Zhang, X., Yuan, Z., Ji, P., Hu, J., & Wei, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111320 · Cited by 81

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 83

The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity

Anderson, K. M., & Gayer, C. P. (2021) · Cells · doi:10.3390/cells10113206 · Cited by 82

Bile Acid Uptake Transporters as Targets for Therapy

Slijepcevic, D., & van de Graaf, S. F. J. (2017) · Digestive Diseases · doi:10.1159/000450983 · Cited by 83

The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease

Aguilar-Olivos, N. E., Carrillo-Córdova, D., Oria‐Hernández, J., Sánchez-Valle, V., Ponciano‐Rodríguez, G., Ramírez-Jaramillo, M., Chablé-Montero, F., Chávez-Tapia, N. C., Uribe, M., & Méndez‐Sánchez, N. (2015) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31170-6 · Cited by 80

Bile acids and their respective conjugates elicit different responses in neonatal cardiomyocytes: role of Gi protein, muscarinic receptors and TGR5

Ibrahim, E., Diakonov, I. A., Arunthavarajah, D., Swift, T., Goodwin-Trotman, M., McIlvride, S., Nikolova, V., Williamson, C., & Gorelik, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25569-4 · Cited by 84

Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice

Chang, S., Kim, Y.-H., Kim, Y.-J., Kim, Y., Moon, S., Lee, Y. Y., Jung, J. S., Kim, Y., Jung, H.-E., Kim, T.-J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01984 · Cited by 81

Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities

Vesterhus, M. N., & Karlsen, T. H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01681-z · Cited by 85

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

Erice, O., Labiano, I., Arbelaiz, A., Santos‐Laso, Á., Muñoz-Garrido, P., Jiménez-Agüero, R., Olaizola, P., Caro‐Maldonado, A., Martín-Martín, N., Carracedo, A., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.016 · Cited by 80

Statins: antimicrobial resistance breakers or makers?

Ko, H. H. T., Lareu, R. R., Dix, B. R., & Hughes, J. (2017) · PeerJ · doi:10.7717/peerj.3952 · Cited by 81

Gut microbiota-derived tryptophan metabolites regulated by Wuji Wan to attenuate colitis through AhR signaling activation

Jing, W., Dong, S., Xu, Y., Liu, J., Ren, J., Liu, X., Zhu, M., Zhang, M., Shi, H., Li, N., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.009 · Cited by 80

Select microbial metabolites in the small intestinal lumen regulate vagal activity via receptor-mediated signaling

Jameson, K. G., Kazmi, S. A., Ohara, T. E., Son, C., Yu, K. B., Mazdeyasnan, D., Leshan, E., Vuong, H. E., Paramo, J., Lopez-Romero, A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111699 · Cited by 88

Advances in Pathogenesis and Management of Pruritus in Cholestasis

Kremer, A. E., Bolier, R., van Dijk, R., Elferink, R. P. J. O., & Beuers, U. H. (2014) · Digestive Diseases · doi:10.1159/000360518 · Cited by 81

Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis

Meng, Q., Chen, X.-L., Wang, C., Liu, Q., Sun, H., Sun, P., Huo, X., Liu, Z., Yao, J., & Liu, K. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.01.020 · Cited by 79

TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling

Masyuk, T. V., Masyuk, A. I., Pisarello, M. J. L., Howard, B. N., Huang, B. Q., Lee, P. Y., Fung, X., Sergienko, E. A., Ardecky, R., Chung, T. D. Y., et al. (2017) · Hepatology · doi:10.1002/hep.29284 · Cited by 77

Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

Manka, P. P., Zeller, A. C., & Syn, W. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 80

Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework

Shah, A., Macdonald, G. A., Morrison, M., & Holtmann, G. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000604 · Cited by 78

Gut Microbiota and its Metabolites: Bridge of Dietary Nutrients and Alzheimer’s Disease

Zhu, G., Zhao, J., Zhang, H., Wang, G., & Chen, W. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.04.005 · Cited by 78

The Lactobacillus as a Probiotic: Focusing on Liver Diseases

Jeong, J., Park, H., Cha, M. G., Park, E., Won, S., Ganesan, R., Gupta, H., Gebru, Y. A., Sharma, S. P., Lee, S. B., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10020288 · Cited by 75

Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases

Xu, Y. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00342 · Cited by 75

Novel and emerging therapies for cholestatic liver diseases

Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 74

Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling

Ciaula, A. D., Bonfrate, L., Baj, J., Khalil, M., Garruti, G., Stellaard, F., Wang, H. H., Wang, D. Q. ‐., & Portincasa, P. (2022) · Nutrients · doi:10.3390/nu14234950 · Cited by 76

TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response

Zheng, M., Zhai, Y., Yu, Y., Shen, J., Chu, S., Focaccia, E., Tian, W., Wang, S., Liu, X., Yuan, X., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.06.008 · Cited by 74

Gut microbiota in non‐alcoholic fatty liver disease and alcohol‐related liver disease: Current concepts and perspectives

Arab, J. P., Arrese, M. A., & Shah, V. H. (2019) · Hepatology Research · doi:10.1111/hepr.13473 · Cited by 76

Therapeutic Targets in Polycystic Liver Disease

Masyuk, T. V., Masyuk, A. I., & LaRusso, N. F. (2017) · Current Drug Targets · doi:10.2174/1389450116666150427161743 · Cited by 71

Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism

Kumari, A., Pathak, D. P., & Asthana, S. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.44774 · Cited by 73

Iron deficiency linked to altered bile acid metabolism promotes Helicobacter pylori–induced inflammation–driven gastric carcinogenesis

Noto, J. M., Piazuelo, M. B., Shah, S. C., Romero–Gallo, J., Hart, J. L., Di, C., Carmichael, J. D., Delgado, A. G., Halvorson, A. E., Greevy, R. A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci147822 · Cited by 73

Dietary fibers as emerging nutritional factors against diabetes: focus on the involvement of gut microbiota

Gowd, V., Xie, L., Zheng, X., & Chen, W. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2019.1576025 · Cited by 70

Publisher Correction: The gut–liver axis and the intersection with the microbiome

Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0031-8 · Cited by 70

Temporal Regulation of the Bacterial Metabolite Deoxycholate during Colonic Repair Is Critical for Crypt Regeneration

Jain, U., Lai, C., Xiong, S., Goodwin, V. M., Lu, Q., Muegge, B. D., Christophi, G. P., VanDussen, K. L., Cummings, B. P., Young, E. R. R., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.07.019 · Cited by 69

Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice

Chèvre, R., Trigueros‐Motos, L., Castaño, D., Chua, T., Corlianò, M., Patankar, J. V., Sng, L., Sim, L., Juin, T. L., Carissimo, G., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201701084rr · Cited by 68

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease

Xu, X., Ocansey, D. K. W., Hang, S., Wang, B., Amoah, S., Yi, C., Zhang, X., Liu, L., & Mao, F. (2022) · Gut Pathogens · doi:10.1186/s13099-022-00499-9 · Cited by 73

In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update

Kury, L. T. A., Abdoh, A., Ikbariah, K., Sadek, B. S., & Mahgoub, M. (2021) · Molecules · doi:10.3390/molecules27010182 · Cited by 68

Gut microbiota and its metabolites – molecular mechanisms and management strategies in diabetic kidney disease

Mao, Z., Gao, Z., Liu, D., Liu, Z., & Wu, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1124704 · Cited by 68

The role of bile acids in functional GI disorders

Appleby, R., & Walters, J. R. F. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12370 · Cited by 66

Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders

Pellicciari, R., Passeri, D., Franco, F., Mostarda, S., Filipponi, P., Colliva, C., Gadaleta, R. M., Franco, P., Carotti, A., Macchiarulo, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01126 · Cited by 67

NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice

Krones, E., Eller, K., Pollheimer, M. J., Racedo, S., Kirsch, A. H., Frauscher, B., Wahlstrom, A. M., Ståhlman, M., Trauner, M. A., Grahammer, F., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.019 · Cited by 66

Review article: therapeutic bile acids and the risks for hepatotoxicity

Ashby, K., Almario, E. N., Tong, W., Borlak, J. T., Mehta, R., & Chen, M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14678 · Cited by 66

The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis

Santamaría, E., Rodríguez‐Ortigosa, C. M., Uriarte, I., Latasa, M. U., Urtasun, R., Álvarez‐Sola, G., Bárcena‐Varela, M., Colyn, L., Arcelus, S., Jiménez, M., et al. (2018) · Hepatology · doi:10.1002/hep.30348 · Cited by 66

Phocea, Pseudoflavonifractor and Lactobacillus intestinalis: Three Potential Biomarkers of Gut Microbiota That Affect Progression and Complications of Obesity-Induced Type 2 Diabetes Mellitus

Wang, Y., Ouyang, M., Gao, X., Wang, S., Fu, C., Zeng, J., & He, X. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s240728 · Cited by 66

Obeticholic acid for the treatment of primary biliary cirrhosis

Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1092381 · Cited by 66

Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease

Wang, C., Zhu, C., Shao, L., Ye, J., Shen, Y., & Ren, Y. (2019) · Mediators of Inflammation · doi:10.1155/2019/7659509 · Cited by 67

Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine

Dvořák, Z., Sokol, H., & Mani, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.013 · Cited by 65

Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena

Bashir, A., Duseja, A. K., De, A., Mehta, M., & Tiwari, P. (2022) · Liver Research · doi:10.1016/j.livres.2022.05.002 · Cited by 65

Deoxycholic Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Exacerbates DSS-Induced Colitis through Promoting Cathepsin B Release

Zhao, S., Gong, Z., Du, X., Tian, C., Wang, L., Zhou, J., Xu, C., Chen, Y., Cai, W., & Wu, J. (2018) · Journal of Immunology Research · doi:10.1155/2018/2481418 · Cited by 64

Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet–fed mice

Takahashi, S., Luo, Y., Ranjit, S., Xie, C., Libby, A. E., Orlicky, D. J., Dvornikov, A. S., Wang, X. X., Myakala, K., Jones, B. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011913 · Cited by 64

The Impact of Gut Microbiota-Derived Metabolites in Autism Spectrum Disorders

Marzal, L. N. P., Prince, N., Bajić, D., Roussin, L., Naudon, L., Rabot, S., Garssen, J., Kraneveld, A. D., & Perez‐Pardo, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810052 · Cited by 67

Dietary Patterns and Gut Microbiota: The Crucial Actors in Inflammatory Bowel Disease

He, P., Yu, L., Tian, F., Zhang, H., Chen, W., & Zhai, Q. (2022) · Advances in Nutrition · doi:10.1093/advances/nmac029 · Cited by 65

Gut microbial metabolites and its impact on human health

Rahman, S. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0809 · Cited by 70

Design and strategies for bile acid mediated therapy and imaging

Nurunnabi, M., Khatun, Z., Revuri, V., Nafiujjaman, M., Cha, S., Cho, S., Huh, K. M., & Lee, Y.-K. (2016) · RSC Advances · doi:10.1039/c6ra10978k · Cited by 64

Cholic acid therapy in Zellweger spectrum disorders

Berendse, K., Klouwer, F. C. C., Koot, B. G. P., Kemper, E. M., Ferdinandusse, S., Koelfat, K. V. K., Leníček, M., Schaap, F. G., Waterham, H. R., Vaz, F. M., et al. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9962-9 · Cited by 64

Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling

Sussman, C. R., Wang, X., Chebib, F. T., & Torres, V. E. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109649 · Cited by 67

Therapeutic potential of T akeda‐ G ‐protein‐receptor‐5 ( TGR5 ) agonists. H ope or hype?

Hodge, R. J., & Nunez, D. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12636 · Cited by 63

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma

Matteo, S. D., Nevi, L., Costantini, D., Overi, D., Carpino, G., Safarikia, S., Giulitti, F., Napoletano, C., Manzi, E., Rose, A. M. D., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210077 · Cited by 63

Chyme reinfusion in patients with intestinal failure due to temporary double enterostomy: A 15-year prospective cohort in a referral centre

Picot, D., Layec, S., Dussaulx, L., Trivin, F., & Thibault, R. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.04.020 · Cited by 61

Fatty acid-binding protein 5 regulates diet-induced obesity via GIP secretion from enteroendocrine K cells in response to fat ingestion

Shibue, K., Yamane, S., Harada, N., Hamasaki, A., Suzuki, K., Joo, E., Iwasaki, K., Nasteska, D., Harada, T., Hayashi, Y., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00543.2014 · Cited by 62

Improvements in Metabolic Syndrome by Xanthohumol Derivatives Are Linked to Altered Gut Microbiota and Bile Acid Metabolism

Zhang, Y., Bobe, G., Revel, J. S., Rodrigues, R. R., Sharpton, T. J., Fantacone, M. L., Raslan, K., Miranda, C. L., Lowry, M. B., Blakemore, P. R., et al. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900789 · Cited by 62

Role of bile acids in liver diseases mediated by the gut microbiome

Shao, J., Ge, T., Chen, S., Wang, G., Yang, Q., Huang, C., Xu, L., & Chen, Z. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.3010 · Cited by 61

Recent advances in metabolism and toxicity of tyrosine kinase inhibitors

Zhao, Q., Wu, Z. E., Li, B., & Li, F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108256 · Cited by 57

The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease

Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 61

Bacterial bile salt hydrolase: an intestinal microbiome target for enhanced animal health

Geng, W., & Lin, J. (2016) · Animal Health Research Reviews · doi:10.1017/s1466252316000153 · Cited by 61

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis

Hu, Y., Liu, X., & Zhan, W. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s170518 · Cited by 60

Pyrrolizidine alkaloids: An update on their metabolism and hepatotoxicity mechanism

Xu, J., Wang, W., Yang, X., Xiong, A., Yang, L., & Wang, Z. (2019) · Liver Research · doi:10.1016/j.livres.2019.11.004 · Cited by 62

A review: Pharmacology and pharmacokinetics of Schisandrin A

Fu, K., Zhou, H., Wang, C., Gong, L., Ma, C., Zhang, Y., & Li, Y. (2022) · Phytotherapy Research · doi:10.1002/ptr.7456 · Cited by 60

Semisynthetic Bile Acid FXR and TGR5 Agonists: Physicochemical Properties, Pharmacokinetics, and Metabolism in the Rat

Roda, A., Pellicciari, R., Gioiello, A., Neri, F., Camborata, C., Passeri, D., Franco, F., Spinozzi, S., Colliva, C., Adorini, L., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214650 · Cited by 59

Bile acid receptors as targets for drug

Schaap, G., Trauner, M. A., & Jansen, P. L. M. (2013)

Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease

Halilbasic, E., Fuchs, C. D., Traussnigg, S., & Trauner, M. (2016) · Digestive Diseases · doi:10.1159/000445268 · Cited by 39

Bile Acid as Therapeutic Agents

Yamanashi, Y., Takada, T., & Suzuki, H. (2017) · Springer eBooks · doi:10.1007/978-4-431-56062-3_5 · Cited by 1

Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases

Xu, Y. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00342 · Cited by 75

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases

Meadows, V., Kennedy, L. L., Kundu, D., Alpini, G. D., & Francis, H. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00015 · Cited by 31